Human growth hormone (hGH) binds to both the growth hormone (GH) and the prolactin (PRL) receptors. Competition experiments followed by mutational analysis show that the epitope on hGH for hPRL receptor consists of strong determinants in the middle of helix 1 (comprising residues His-18, His-21, and Phe-25), a loop region (including , and the central portion of helix 4 (containing residues Arg-167, Lys-168, Lys-172, Glu-174, . When these residues are mapped on a structural model of hGH, they form a patch that overlaps but is not identical to that previously determined for the hGH receptor. Three of these side chains (His-18, His-21, and Glu-174) are ligands for binding Zn2+, which is required for high-affinity hGH-hPRL receptor complex formation. By introducing pairs of mutations into hGH that exploit the zinc dependency for hPRL receptor binding and remove side chains in the nonoverlapping regions, we have shifted the binding preference toward the hGH receptor by a factor of 34,000 or toward the hPRL receptor by a factor of 150 without substantial loss in binding affinity for the preferred receptor. The energetic effects of the individual mutations are additive within the double mutants, suggesting that each functions independently and does not introduce gross perturbations in structure. Such receptorselective variants of hGH should be useful molecular probes to link specific receptor binding events to the various biological activities of hGH.
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Human growth hormone (hGH) elicits a myriad of biological effects including linear growth, lactation, nitrogen retention, diabetogenic and insulin-like effects, and macrophage activation (1) (2) (3) (4) . Each of these effects begins with the interaction of hGH with specific cellular receptors (5) . Thus far, the only cloned human genes whose products bind hGH are the hGH receptor from liver (6) and the human prolactin (hPRL) receptor from mammary gland (7) . However, there may be other receptors that bind hGH, including the placental lactogen (PL) receptor (8) .
The hGH and hPRL receptors (6, 7) contain an extracellular hormone binding domain (consisting of 246 and 211 residues, respectively) that share 32% sequence identity, a single transmembrane domain, and a cytoplasmic domain that differs widely in sequence and length. Nonglycosylated forms of the extracellular binding domains of the hGH and hPRL receptors (hGHbp and hPRLbp, respectively) can be expressed in large quantities in Escherichia coli. These highly purified recombinant binding proteins retain the same affinity for hGH and specificity as their natural glycosylated counterparts (9, 10) and are extremely useful reagents for efficient assessment of the binding affinity for mutants of hGH (9) (10) (11) (12) (13) .
It is not known whether the binding sites on hGH for the hGH and hPRL receptors are identical or which receptor (or combination of receptors) is responsible for which pharmacological effect. To address these issues, we have mapped binding determinants on hGH for the hGH and hPRL receptors and showed that they overlap but are not identical. Using this information, we designed receptor-specific variants of hGH that should be useful as probes to link binding to either receptor with particular biological activities.
MATERIALS AND METHODS
The hGHbp and hPRLbp were expressed in E. coli and purified on hGH affinity columns (9, 10) . Mutants of hGH were produced by site-directed mutagenesis (14) as described (10) (11) (12) . The mutated hormones were expressed in E. coli (15) and purified by (NH4)2SO4 precipitation to 60o% homogeneity (11) . Control experiments show that the residual E. coli contaminants do not affect the binding assays, which are performed at high dilution of the mutated hGH analog and in the presence of 0.1% bovine serum albumin.
The binding constants for variants of hGH to the hGHbp were measured by competitive displacement of 1251-labeled hGH (1251-hGH) from the hGHbp as described (6, (9) (10) (11) (12) . A monoclonal antibody to the hGHbp (mAb5, obtained from Agen, Parsippany, NJ; ref. 16 ) was used to precipitate the 1251-hGHIhGHbp complex. Zinc-dependent binding of the hGH mutants to the hPRLbp was measured by competitive displacement of 1251-hGH as described for the hGHbp (6, 9) except that assays included 50 AM ZnCl2 and 10 mM MgCl2 (10) . Zinc-independent binding was measured by identical methods except 1251-hPRL was used as the labeled ligand, since it binds hPRLbp tightly in the absence ofZn2+ (10) . This assay buffer included 1 mM EDTA without ZnCl2 or MgCl2. Affinity-purified rabbit polyclonal antibodies raised against the hPRLbp were used to precipitate the 125I-hGH hPRLbp complex (10) . Under these conditions, hGH forms a 1:1 complex with either the hGHbp or hPRLbp.
RESULTS
The hPRL and hGH Receptor Binding Sites on hGH Overlap but Are Not Identical. Previous studies have shown that the binding affinity of hGH to the hPRLbp is enhanced >8000-fold in the presence of ZnCl2 (10). The hPRLbp is able to competitively displace the hGHbp from hGH with an IC50 of 120 pM (Fig. 1) (Table 1) . In this approach, variants of hGH that contained segment substitutions (7-30 residues long) derived from a nonbinding homolog, pGH, or binding-competent homologs, hPRL and hPL, were analyzed for binding to the hPRLbp. As expected, virtually all of the substitutions tested from the bindingcompetent hormones, hPRL and hPL, do not disrupt binding to hPRLbp. The only exception is hPRL residues 22-33, which causes a 15-fold reduction in binding affinity to the hPRLbp. In contrast, the hGH mutants containing segments of pGH-namely, pGH residues 11-33 and pGH residues 57-73-cause large disruptions in binding affinity for the hPRLbp, whereas pGH residues 48-52 have no effect. Thus, binding to the hPRLbp is very sensitive to mutations in hGH near the central portion of helix 1 and the loop region between residues 57 and 73.
Several of the segment substituted variants cause substantial changes in receptor binding preference (Table 1) , suggesting that the hPRL and hGH receptor epitopes are not identical. For example, the binding affinity of variants substituted with hPRL residues 22-33 or pGH residues 11-33 are 18-and 130-fold lower, respectively, for the hPRLbp than for the hGHbp. In contrast, the hPL residues 56-64 and hPRL residues 54-74 have almost no effect on binding to the hPRLbp, yet they weaken binding to the hGHbp by factors of 30 and 69, respectively. These preferential receptor binding effects for the hGH mutants coupled with their unaltered binding properties for a number ofmonoclonal antibodies (11) indicate that reductions in receptor binding affinity are caused by local and not global structural changes in the variant hormones.
High-Resolution Functional Map, of the hPRL R Bing Site. We next identified specific side chains in hGH that strongly modulate binding to the hPRLbp by alaninescanning mutagenesis (Table 2 ). In addition to analyzing the two regions implicated by homolog scanning to be involved in binding, we also scanned the helix 4 region because it is located between helix 1 and the 54-74 loop region ( Fig. 2) and had previously been shown to contain a number of residues that strongly modulate hGH affinity for the hGHbp (12) . The alanine substitutions causing a >4-fold reduction in binding affinity to the hPRLbp are in the central portion of helix 1 (including residues His-18, His-21, and Phe-25), a loop region (including Ile-58, Asn-63, and Ser-62), and the middle ofhelix 4 (comprising Arg-167, Lys-168, Lys-172, Glu-174, Phe-176, and Arg-178). These 12 residues form a patch when mapped on a structural model of hGH ( Fig. 2A) . The most disruptive alanine substitutions in helix 1 and helix 4 project in the same direction as shown by the helix wheel diagrams. N12A  L1SA  R16A  H18A  R19A  H21A  F25A  D26E  F54A  SSSA  E56A  S57A  158A  P59A  S62A   N63A  R64A  E65A  E66A  Q68A  Q69A  K70A  S71A  L73A  Y160A  Y164A  R167A  K168A  D171A  K172A  E174A  T175S  F176A  R178A  1179A  1179M  V180A  Q181A  R183A  S184A  V185A  E186A  G187A Three residues (His-18, His-21, and Glu-174) along with His-188 from the hPRLbp are proposed to comprise the binding site for Zn2+ that is required for tight binding of hGH to the hPRLbp (10). For example, in the absence of zinc the alanine mutants of the zinc ligands in hGH have essentially the same affinity for the hPRLbp as does wild-type hGH. Here, we extend these studies ( Table 3 ) and show that the relative disruptive effects of alanine mutants at two basic Fig. 2 A and B) overlap but do not superimpose. For example, Ile-58, Lys-172, and Phe-176 are important for binding to both receptors (Fig. 2C) . Other determinants are more important for binding to the hPRLbp (especially those involved in the Zn2+ site) and for selective binding of hGHbp (notably, Phe-10, Glu-56, Asp-171, and Arg-64). These data suggest that not all of the binding determinants for recognizing hGH are the same in the hGH and hPRL receptors.
We reasoned that it should be possible to design receptorspecific variants ofhGH by combining two receptor-selective single alanine mutants. Indeed, when two single mutants that preferentially disrupt binding hPRLbp (K168A and E174A) are combined, the double mutant exhibits a 34,000-fold shift in preference for binding to the hGHbp (Table 4 ). The preference for binding the hPRLbp over the hGHbp can be enhanced nearly 150-fold by combining R64A and D171A. These receptor-selective hGH variants (K168A/E174A or R64A/D171A) do not substantially reduce the affinity for the preferred receptor (hGHbp or hPRLbp, respectively). It is also possible to reduce binding to both receptors simultaneously. For example, combining K172A and F176A, which individually cause large reductions in binding affinity to both receptors, produces much larger disruptions in affinity (500-to 8000-fold) than either of the two single mutants.
The changes in the free energy of binding (AAGbjnding) upon introduction of two mutations into hGH are strikingly additive (Table 5 ). This suggests that these mutant residues paired in the multiple mutants function independently and do not grossly perturb the structure of hGH (for review, see ref. 
DISCUSSION
We have presented a systematic mutational strategy for identifying residues that modulate binding of hGH to two different receptors. We determined functionally important side chains on hGH by scanning-mutational analysis and showed that the binding epitopes overlap but are not identical. By mutating the nonoverlap residues, we have produced analogs of hGH that alter binding to either or both receptors. Combinations of these mutations have additive effects on binding and can be used to engineer hGH variants with altered receptor specificities.
The mutational analyses show that there are significant differences between the epitopes on hGH for the hGHbp and hPRLbp (Fig. 2) . For example, with Zn2+ bound, the net charge in the epitope on hGH for the hPRLbp is +5 (defined by residues causing .4-fold reduction in affinity; Fig. 2A ). This strongly electropositive charge cluster is surrounded by a series of important hydrophobic residues (Phe-25, Ile-58, Tyr-164, and Phe-176). Zinc is not required for formation of the hGH-hGHbp complex and the hGHbp epitope (Fig. 2B) is notably less electropositive (net charge for residues causing .4-fold disruptions, +1). The most disruptive alanine substitution in hGH for the hGHbp was a 58-fold reduction We have previously shown (12) that the E174A mutation in hGH enhances binding to the hGHbp by a factor of 4. Here, we find that H21A enhances binding to the hGHbp by a factor of 3. Both of these residues are required for zinc-mediated binding of hGH to the hPRLbp ( Fig. 2A) . Thus, to maintain the dual binding role of hGH to the hGH and hPRL receptors, the hormone has had to compromise binding to the hGH receptor by incorporating ligands to bind zinc in the overlapping epitope for the hPRL receptor.
Residues that cause large changes in receptor binding affinity may do so by indirect effects. However, we believe that the majority of the disruptive effects observed here are due to local structural changes because virtually all of the single mutants tested retain full binding affinity to eight different hGH monoclonal antibodies (11, 12) . In addition, the mutants often lead to changes in receptor binding preference and not global disruptions in affinity for both receptors (Tables 1 and 2 ).
Two recent studies (19, 20) present some data on the location of the lactogenic binding site on hGH. Retegui and coworkers (19) using monoclonal antibodies suggested that part of the lactogenic site is located in helix 1 (residues 1-32).
Gertler and coworkers (20) 26) . By analogy, the receptor-specific variants ofhGH should be key reagents for probing the role of the hGH and hPRL receptors in the complex pharmacology of hGH, and for identifying other receptors for hGH.
